NAION risk with semaglutide: what we know so far
Eye (Lond)
.
2025 Jun;39(9):1655-1656.
doi: 10.1038/s41433-025-03833-y.
Epub 2025 May 7.
Authors
Alan Y Hsu
1
,
Yu-Hsun Wang
2
,
Chun-Ju Lin
3
4
5
,
Ning-Yi Hsia
1
6
7
,
Yi-Ching Shao
1
6
8
,
Chun-Chi Chiang
1
6
7
,
Huan-Sheng Chen
9
,
Yi-Yu Tsai
1
6
7
,
James Cheng-Chung Wei
10
11
12
Affiliations
1
Department of Ophthalmology, China Medical University Hospital, China Medical University, Taichung, Taiwan.
2
Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.
3
Department of Ophthalmology, China Medical University Hospital, China Medical University, Taichung, Taiwan. doctoraga@gmail.com.
4
School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan. doctoraga@gmail.com.
5
Department of Optometry, Asia University, Taichung, Taiwan. doctoraga@gmail.com.
6
School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
7
Department of Optometry, Asia University, Taichung, Taiwan.
8
Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung, Taiwan.
9
An-Shin Dialysis Center, Excelsior Renal Service Co., Ltd. Taiwan Branch, Taichung, Taiwan.
10
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
11
Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
12
Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.
PMID:
40335680
PMCID:
PMC12130526
(available on
2026-06-01
)
DOI:
10.1038/s41433-025-03833-y
No abstract available
Publication types
Editorial